BioNTech to establish regional HQ, mRNA manufacturing facility in Singapore


FILE PHOTO: A healthcare worker prepares a dose of the Pfizer/BioNTech coronavirus disease (COVID-19) vaccine, which was authorized by Canada to be used for children aged 12 to 15, at Woodbine Racetrack pop-up vaccine clinic in Toronto, Ontario, Canada May 5, 2021. REUTERS/Carlos Osorio

SINGAPORE: BioNTech SE today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for southeast Asia in Singapore.

The German biotechnology company also plans to establish a fully integrated messenger RNA (mRNA) manufacturing facility in the republic with support from the Singapore Economic Development Board.

"Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities,” said its Chief Executive and Co-founder, Ugur Sahin, in its website.

"With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” he said.

The new facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, as well as a rapid response production capability for southeast Asia to address potential pandemic threats.

BioNTech plans to open its Singapore office and initiate construction of the manufacturing facility in 2021, subject to planning approval.

The company anticipates that the site could be operational as early as 2023 and will create up to 80 jobs in Singapore.

BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

BioNTech is among the handful of biotechnology companies that has succeeded in producing the COVID-19 vaccine which boasts for 95 percent efficacy rate. - Bernama
Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3

BioNTech , RNA , Ugur Sahin , biotechnology , vaccine , Singapore

   

Next In Business News

Australian central bank among those hit by widespread internet outages
Euro Holdings cancels proposed bonus issue after steep plunge
CPO futures reverses gains as India puts import tax cut plans on hold
Advancecon buys 51% stake in loss making quarry operator for RM30.4mil
MSM says sugar demand stable despite lockdown
N. American oil service firms' pricing and hiring on the upswing
FBM KLCI falls for third straight day, down 7.46 points
Govt approves wage subsidy applications worth RM1.215bil as at June 4
Zafrul: RM12.12bil approved under SME soft loan fund as at June 4
Crude oil prices fall on stronger U.S. dollar

Stories You'll Enjoy


Vouchers